Cancer Genetics Inc (NASDAQ:CGIX) – Equities research analysts at Dawson James issued their FY2017 earnings per share estimates for Cancer Genetics in a research report issued to clients and investors on Monday. Dawson James analyst R. Wasserman expects that the medical research company will post earnings of ($0.75) per share for the year. Dawson James also issued estimates for Cancer Genetics’ Q4 2017 earnings at ($0.12) EPS and FY2018 earnings at ($0.30) EPS.
Several other analysts also recently issued reports on CGIX. HC Wainwright set a $6.00 price target on shares of Cancer Genetics and gave the company a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research raised shares of Cancer Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. ValuEngine downgraded shares of Cancer Genetics from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, Maxim Group set a $6.00 price objective on shares of Cancer Genetics and gave the company a “buy” rating in a research note on Wednesday, December 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Cancer Genetics presently has an average rating of “Hold” and a consensus target price of $5.56.
Shares of Cancer Genetics (NASDAQ:CGIX) opened at $2.00 on Wednesday. Cancer Genetics has a fifty-two week low of $1.75 and a fifty-two week high of $5.30. The stock has a market cap of $55.41, a PE ratio of -2.44 and a beta of 1.10. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01.
Cancer Genetics (NASDAQ:CGIX) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). Cancer Genetics had a negative net margin of 54.65% and a negative return on equity of 46.21%.
In other news, Director John Pappajohn acquired 150,000 shares of Cancer Genetics stock in a transaction that occurred on Friday, December 8th. The shares were acquired at an average price of $1.86 per share, with a total value of $279,000.00. Following the completion of the purchase, the director now owns 2,781,204 shares of the company’s stock, valued at approximately $5,173,039.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 21.30% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in CGIX. Northern Trust Corp lifted its stake in shares of Cancer Genetics by 61.0% during the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares during the period. Vanguard Group Inc. lifted its stake in shares of Cancer Genetics by 61.9% during the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares during the period. Granahan Investment Management Inc. MA lifted its stake in shares of Cancer Genetics by 26.3% during the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after buying an additional 49,371 shares during the period. Finally, Perkins Capital Management Inc. lifted its stake in shares of Cancer Genetics by 22.7% during the fourth quarter. Perkins Capital Management Inc. now owns 989,700 shares of the medical research company’s stock valued at $1,831,000 after buying an additional 183,000 shares during the period. 11.08% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Cancer Genetics Inc (CGIX) Expected to Earn FY2017 Earnings of ($0.75) Per Share” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/01/cancer-genetics-inc-cgix-expected-to-earn-fy2017-earnings-of-0-75-per-share.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.